Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2025-12-25 @ 2:29 PM
NCT ID:
NCT00544466
Group ID:
EG000
Title:
Treatment (Enzyme Inhibitor, Radiation Therapy, Transplant)
Description:
PREPARATIVE REGIMEN\*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: \*Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
fludarabine phosphate: 25 mg/m2 day -7 through day -3 prior to transplant
melphalan: 140 mg/m2 day -2 prior to transplant
allogeneic hematopoietic stem cell transplantation: Cells infused on Day 0 of transplant regimen
intensity-modulated radiation therapy: Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
Deaths Number Affected:
43
Deaths Number At Risk:
None
Serious Number Affected:
13
Serious Number At Risk:
62
Other Number Affected:
61
Other Number At Risk:
62
Study:
NCT00544466
Results Section:
NCT00544466
Adverse Events Module:
NCT00544466